There is still a balance of P10.05 billion under the Bayanihan to Recover as One Act or Bayanihan 2 yet to be utilized as of end-September, the Department of Budget and Management (DBM) reported Monday.
Data released by the DBM showed that agencies have obligated P204.07 billion out of the P214.12 billion allotment released, equivalent to an obligation rate of 95.3%.
There is still a balance of P10.05 billion under the Bayanihan to Recover as One Act or Bayanihan 2 yet to be utilized as of end-September, the Department of Budget and Management (DBM) reported Monday.
Data released by the DBM showed that agencies have obligated P204.07 billion out of the P214.12 billion allotment released, equivalent to an obligation rate of 95.3%.
Under the Bayanihan to Heal as One Act or Bayanihan 1, the DBM said, agencies have obligated a total of P369.08 billion from the P387.93 billion allotment released to them.
A total of P10.10 billion charged against the 2020 budget are still valid for disbursement until the end of the year.
Other releases outside the Bayanihan laws are recorded at P88.21 billion, largely coming from the 2021 budget with P81.75 billion. The DBM said there are still some P23.38 billion that need to be obligated and P42.84 billion that need to be disbursed by the end of the year.
“The DBM commits to continuously support all implementing agencies as they respond to the pandemic to ensure that all Filipinos are given the assistance and services they need, especially during these challenging times,” the DBM said.
The same data showed that the DBM has released a total of P690.26 billion as of end-September to support the COVID-19 response programs of various government agencies.
Out of the funds, P637.97 billion or 92.4% has been obligated while P570.04 billion or 89.4% has been disbursed.
Releases in the July to September period were charged from the 2021 budget, as the funds under the Bayanihan laws expired in June. These include the payment of the COVID-19 special risk allowance of health workers.
The releases also cover the purchase of COVID-19 vaccine ancillaries, the procurement of RT-PCR testing kits, and the renewal of contracts for hiring of healthcare professionals, among others.
